Hypersensitivity reactions to HIV therapy

被引:58
作者
Chaponda, Mas [1 ]
Pirmohamed, Munir [1 ]
机构
[1] Univ Liverpool, Wolfson Ctr Personalised Med, Dept Pharmacol & Therapeut, Liverpool L69 3GL, Merseyside, England
基金
英国惠康基金;
关键词
abacavir; drug hypersensitivity; nevirapine; pharmacogenetics; S[!text type='JS']JS[!/text; TEN; HUMAN-LEUKOCYTE ANTIGEN-B-ASTERISK-5701; PNEUMOCYSTIS-CARINII-PNEUMONIA; TREATMENT-EXPERIENCED PATIENTS; TIPRANAVIR PLUS RITONAVIR; HLA-B REGION; ABACAVIR HYPERSENSITIVITY; INFECTED PATIENTS; ANTIRETROVIRAL THERAPY; TRIMETHOPRIM-SULFAMETHOXAZOLE; NAIVE PATIENTS;
D O I
10.1111/j.1365-2125.2010.03784.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Many drugs used for the treatment of HIV disease (including the associated opportunistic infections) can cause drug hypersensitivity reactions, which vary in severity, clinical manifestations and frequency. These reactions are not only seen with the older compounds, but also with the newer more recently introduced drugs. The pathogenesis is unclear in most cases, but there is increasing evidence to support that many of these are mediated through a combination of immunologic and genetic factors through the major histocompatibility complex (MHC). Genetic predisposition to the occurrence of these allergic reactions has been shown for some of the drugs, notably abacavir hypersensitivity which is strongly associated with the class I MHC allele, HLA-B*5701. Testing before the prescription of abacavir has been shown to be of clinical utility, has resulted in a change in the drug label, is now recommended in clinical guidelines and is practiced in most Western countries. For most other drugs, however, there are no good methods of prevention, and clinical monitoring with appropriate (usually supportive and symptomatic) treatment is required. There is a need to undertake further research in this area to increase our understanding of the mechanisms, which may lead to better preventive strategies through the development of predictive genetic biomarkers or through guiding the design of drugs less likely to cause these types of adverse drug reactions.
引用
收藏
页码:659 / 671
页数:13
相关论文
共 141 条
[1]   Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers [J].
Abel, Samantha ;
van der Ryst, Elna ;
Rosario, Maria C. ;
Ridgway, Caroline E. ;
Medhurst, Christine G. ;
Taylor-Worth, Richard J. ;
Muirhead, Gary J. .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 65 :5-18
[2]   Pharmacokinetics, safety and tolerability of a single oral dose of maraviroc in HIV-negative subjects with mild and moderate hepatic impairment [J].
Abel, Samantha ;
Davis, John D. ;
Ridgway, Caroline E. ;
Hamlin, Julia C. ;
Vourvahis, Manoli .
ANTIVIRAL THERAPY, 2009, 14 (06) :831-837
[3]  
Akerlund B, 1997, J INFECTION, V35, P143, DOI 10.1016/S0163-4453(97)91578-4
[4]   Slow acetylator phenotype and genotype in HIV-positive patients with sulphamethoxazole hypersensitivity [J].
Alfirevic, A ;
Stalford, AC ;
Vilar, FJ ;
Wilkins, EGL ;
Park, BK ;
Pirmohamed, M .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2003, 55 (02) :158-165
[5]  
Alfirevic A, 2009, PHARMACOGENOMICS, V10, P531, DOI [10.2217/pgs.09.6, 10.2217/PGS.09.6]
[6]   Incidence and risk factors for rash in Thai patients randomized to regimens with nevirapine, efavirenz or both drugs [J].
Ananworanich, J ;
Moor, Z ;
Siangphoe, U ;
Chan, J ;
Cardiello, P ;
Duncombe, C ;
Phanuphak, P ;
Ruxrungtham, K ;
Lange, J ;
Cooper, DA .
AIDS, 2005, 19 (02) :185-192
[7]   Efficacy and safety of darunavir/ritonavir in treatment-experienced HIV type-1 patients in the POWER 1, 2 and 3 trials at week 96 [J].
Arasteh, Keikawus ;
Yeni, Patrick ;
Pozniak, Anton ;
Grinsztejn, Beatriz ;
Jayaweera, Dushyantha ;
Roberts, Afsoon ;
Hoy, Jennifer ;
De Meyer, Sandra ;
Vangeneugden, Tony ;
Tomaka, Frank .
ANTIVIRAL THERAPY, 2009, 14 (06) :859-864
[8]   Prevention of nevirapine-associated exanthema using slow dose escalation and/or corticosteroids [J].
Barreiro, P ;
Soriano, V ;
Casas, E ;
Estrada, V ;
Téllez, MJ ;
Hoetelmans, R ;
de Requena, DG ;
Jiménez-Nácher, I ;
González-Lahoz, J .
AIDS, 2000, 14 (14) :2153-2157
[9]   SCORTEN: A severity-of-illness score for toxic epidermal necrolysis [J].
Bastuji-Garin, S ;
Fouchard, N ;
Bertocchi, M ;
Roujeau, JC ;
Revuz, J ;
Wolkenstein, P .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2000, 115 (02) :149-153
[10]   Severe abacavir hypersensitivity reaction in a patient tested HLA-B*5701 negative [J].
Bonta, Peter I. ;
Vermeulen, Loost N. ;
Speelman, Peter ;
Prins, Jan M. .
AIDS, 2008, 22 (12) :1522-1523